Authors



Dawn M. Parsons, RPh, MBA

Latest:

Moving From A to Z: Successful Implementation of a Statin Switch Program by a Large Physician Group

This report shows that a successful, cost-effective statin switch program can be implemented by a large physician group via a centralized, collaborative process.





Donna Pillitterre Dugan, MS

Latest:

Availability of Data for Measuring Physician Quality Performance

Typical health plan data provide limited information for benchmarking physician performance using even a less stringent rule for attributing patient measures to physicians.


Yeon-Hee Baek, BA

Latest:

Prescribing Trend of Pioglitazone After Safety Warning Release in Korea

The pioglitazone safety warning issued in South Korea, which recommended prescribing with careful attention among those with high risk of bladder cancer, led to a moderate decrease in pioglitazone users.


Howard Cabral, PhD

Latest:

Health Insurance Design and Conservative Therapy for Low Back Pain

This study examined the association between health insurance design features and choice of physical therapy or chiropractic care by patients with new-onset low back pain.



Johnna D. Anderson, MS

Latest:

Adherence and Dosing Frequency of Common Medications for Cardiovascular Patients

In this database analysis, greater adherence was observed for once-daily dosing compared with twice-daily dosing with chronic-use prescription medications used by patients with cardiovascular disease.



Farzaneh Shirani, MD

Latest:

Emergency Department Nonurgent Visits in Iran: Prevalence and Associated Factors

Inappropriate use of emergency department resources in Iran is a frequent problem that calls for effective approaches and interventions.


Nikoletta M. Margaretos, BA

Latest:

Patients’ Access to 2018 FDA-Approved Drugs 1 Year Post Approval

2018 was a landmark year for new drug approvals. However, patients’ access to these novel drugs varied by drug category and enrolled health plan.



Rachel R. Bailey, MPH

Latest:

Economic Model for Emergency Use Authorization of Intravenous Peramivir

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.


Elizabeth G. Liles, MD

Latest:

More Comprehensive Discussion of CRC Screening Associated With Higher Screening

More comprehensive discussion of colorectal screening by primary care physicians was associated with higher screening rates among adults aged 51 to 80 years who were overdue for screening.




Anjali Sharma, MD

Latest:

Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia

This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.


Laura Mortkowitz

Latest:

The Great Biomarker Chase

Promise and Pitfalls Along the Path to Personalized Care


Rebecca A. Malouin, PhD, MPH, MS

Latest:

Multipayer Primary Care Transformation: Impact for Medicaid Managed Care Beneficiaries

The Michigan Primary Care Transformation project generated cost savings among adults in Medicaid managed care, particularly high-risk adults, while largely maintaining quality of care.


Sean Bowman, MPH

Latest:

Evaluating the Efficacy of a Bundled Chronic Condition Management Program

A chronic disease management company presents promising preliminary results from their remote intensive behavioral counseling intervention, aimed at addressing type 2 diabetes.


Krista Drobac

Latest:

Telehealth: An Important Tool in Achieving the Goals of the ACO Program and Why Restrictions Should Be Lifted in Final ACO Rule

Lifting section 1834(m) restrictions on telehealth services would help ACOs to utilize this beneficial tool to achieve their cost, quality, access, and patient engagement goals.





Katerine Dea, MSc

Latest:

Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer

This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.



Elise M. Pelletier, MS

Latest:

Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis

Out-of-pocket payments differ widely among oral oncolytic options. As cost for therapy becomes a greater part of treatment decisions, an understanding of patient out-of-pocket cost will be critical in informing choices.


AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo